Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Momenta Pharmaceuticals, Inc.    MNTA

MOMENTA PHARMACEUTICALS, INC.

(MNTA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
31.88(c) 32.83(c) 33.79(c) 33.96(c) 33.8(c) Last
1 087 800 969 651 885 275 737 678 1 814 191 Volume
+0.76% +2.98% +2.92% +0.50% -0.47% Change
More quotes
Financials (USD)
Sales 2019 21,5 M
EBIT 2019 -263 M
Net income 2019 -260 M
Finance 2019 150 M
Yield 2019 -
Sales 2020 21,0 M
EBIT 2020 -213 M
Net income 2020 -219 M
Finance 2020 99,6 M
Yield 2020 -
P/E ratio 2019 -12,9x
P/E ratio 2020 -16,4x
EV / Sales2019 166x
EV / Sales2020 173x
Capitalization 3 719 M
More Financials
Company
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer... 
More about the company
Surperformance© ratings of Momenta Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on MOMENTA PHARMACEUTICALS, I
02/19Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Heal..
GL
02/12Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Fi..
GL
01/14MOMENTA PHARMACEUTICALS : Announces CFO Transition
AQ
01/13MOMENTA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Reg..
AQ
01/13Momenta Provides Year-End 2019 Update and 2020 Outlook
GL
01/06MOMENTA PHARMACEUTICALS : Announces CFO Transition
AQ
01/03Momenta Pharmaceuticals Announces CFO Transition
GL
01/03MOMENTA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-..
AQ
2019Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morga..
GL
2019MOMENTA PHARMACEUTICALS : Appoints Dr. Jane F. Barlow to Board of Directors
AQ
2019MOMENTA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-..
AQ
2019MOMENTA PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
2019Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors
GL
2019MOMENTA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
AQ
2019MOMENTA PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
More news
News in other languages on MOMENTA PHARMACEUTICALS, I
02/21Berenberg hebt Ziel für Akzo Nobel auf 75 Euro - 'Sell'
01/30Berenberg hebt Lanxess auf 'Buy' - Ziel 63 Euro
2019MOMENTA PHARMACEUTICALS, INC. : Veröffentlichung des Jahresergebnisses
2019MOMENTA PHARMACEUTICALS, INC. : publication des résultats annuels
2016Teva plant nach Übernahme von Allergan-Generikasparte weitere Zukäufe
More news
Analyst Recommendations on MOMENTA PHARMACEUTICALS, I
More recommendations
Sector news : Biotechnology & Medical Research - NEC
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart MOMENTA PHARMACEUTICALS, INC.
Duration : Period :
Momenta Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOMENTA PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 35,30  $
Last Close Price 33,80  $
Spread / Highest target 47,9%
Spread / Average Target 4,44%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
Craig A. Wheeler President, Chief Executive Officer & Director
Bruce L. Downey Chairman
Young T. Kwon Chief Financial & Business Officer
Santiago Arroyo Chief Medical Officer & Senior VP-Development
Anthony M. Manning Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOMENTA PHARMACEUTICALS, INC.71.31%3 719
LONZA GROUP18.80%31 846
IQVIA HOLDINGS INC.5.77%31 512
SEATTLE GENETICS, INC.2.40%20 154
CELLTRION, INC.--.--%19 564
INCYTE CORPORATION-7.36%17 535